| Nov 13 |
Tyra Biosciences to Present at Upcoming Investor Conferences
|
| Nov 8 |
Tyra Biosciences GAAP EPS of -$0.41 beats by $0.06
|
| Nov 7 |
Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights
|
| Nov 3 |
Chief Financial Officer of Tyra Biosciences Alan Fuhrman Buys 284% More Shares
|
| Oct 28 |
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)
|
| Oct 25 |
Tyra stock plunges 17% amid TYRA-300 study data release
|
| Oct 24 |
Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)
|
| Oct 23 |
Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET
|
| Oct 21 |
Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point
|
| Oct 20 |
Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation
|
